Apigenin for Health & Longevity

Evidence Review created on 05/02/2026 using AI4L / Opus 4.7

Also known as: 4’,5,7-Trihydroxyflavone, Apigenine, Spigenin, Chamomile Flavone

Motivation

Apigenin is a yellow plant flavone found in chamomile flowers, parsley, celery, and several culinary herbs. Interest in concentrated apigenin rose sharply over the past decade along two lines: a sleep-supporting effect attributed to chamomile-derived apigenin, and a possible longevity effect linked to its activity on cellular energy-metabolism pathways tied to aging.

Dietary sources include parsley, celery, chamomile tea, and to a lesser extent oranges, oregano, thyme, and artichoke. Concentrated supplements typically deliver 50 mg per capsule, modeled on doses popularized in widely shared sleep-stack protocols. Proponents emphasize a preclinical profile spanning multiple aging-related pathways in cells, worms, flies, and rodents, while skeptics note that very few rigorous human trials of isolated apigenin have been published, with most evidence resting on chamomile preparations of varying flavone content.

This review examines the current evidence on apigenin as a health and longevity intervention, including its mechanisms, plausible benefits, known risks, sourcing, and practical factors relevant to long-term use.

Benefits - Risks - Protocol - Conclusion

Recommended Reading

This section highlights expert commentary, articles, and educational resources providing accessible high-level overviews of apigenin’s health and longevity effects.

• Do These Sleep Supplements Actually Work? (Magnesium, Apigenin, and Theanine) - Rhonda Patrick

  A FoundMyFitness Q&A segment in which Rhonda Patrick directly addresses whether apigenin improves sleep, discusses dietary sources (parsley, celery, chamomile tea), and compares apigenin’s evidence base to magnesium and theanine, with a candid acknowledgment that human data on isolated apigenin is sparse.

• Toolkit for Sleep - Andrew Huberman

  A Huberman Lab newsletter that lists 50 mg of apigenin taken 30–60 minutes before bedtime as one of three supplements in his widely shared sleep cocktail, alongside magnesium threonate or bisglycinate and L-theanine, with the rationale that apigenin reduces ruminating thoughts via GABA (gamma-aminobutyric acid, the brain’s main inhibitory neurotransmitter)-related and anxiolytic-like activity.

• AMA #42: Optimizing Sleep – Bedtime Routine, Molecule Regimen, Sleep Trackers, Sauna, & More - Peter Attia

  An ask-me-anything episode in which Peter Attia walks through his bedtime supplement regimen, discusses apigenin’s mechanism of action and dosing, and frames it as a “reasonable to try, not essential” addition that would not anchor a sleep protocol but is acceptable when foundational sleep habits are in place.

• What Do Phytochemicals Do for Your Health? - Lindsay Christensen

  A long-form Chris Kresser article on plant bioactives that situates apigenin within the broader flavonoid class and the xenohormesis framework, noting its anti-inflammatory and antiviral activity and its likely role as a hormetic, mildly stress-inducing compound rather than a direct nutrient.

• How Vegetable Extracts Protect Against Cancer - Rita Haven

  A Life Extension Magazine feature focused on apigenin as a polyphenol with anticancer activity, summarizing the proposed mechanisms (NF-κB (Nuclear Factor kappa-light-chain-enhancer of activated B cells, a transcription factor central to inflammatory gene expression) inhibition, cell-cycle arrest, antioxidant defense, induction of apoptosis) and the cruciferous-vegetable synergies, written from a supplement-industry-aligned perspective and useful as a counterpoint to academic skeptics of clinical translation.

Grokipedia

Apigenin - Grokipedia

The Grokipedia article provides a thorough technical overview of apigenin chemistry — flavone structure, hydroxylation pattern, dietary sources, and known pharmacology — alongside its proposed mechanisms across antioxidant, anti-inflammatory, anticancer, neuroprotective, sleep-promoting, and CD38 (Cluster of Differentiation 38, a glycoprotein that consumes cellular NAD+ (nicotinamide adenine dinucleotide, a coenzyme central to cellular energy metabolism))-inhibiting NAD+-elevating pathways.

Examine

Apigenin - Examine

The Examine apigenin page summarizes the compound’s biological effects on anxiety, brain function, oxidative stress, inflammation, and hormonal regulation, while emphasizing that nearly all current evidence is preclinical, that isolated apigenin has poor stability and oral bioavailability, and that human safety and drug-interaction data remain limited.

ConsumerLab

Apigenin: Health Effects & Safety - ConsumerLab

The ConsumerLab CL Answer reviews the marketing claims for apigenin (cancer, insomnia, mood, cognition, kidney protection, blood pressure, blood sugar, menopausal and PCOS (Polycystic Ovary Syndrome, a hormonal disorder common among women of reproductive age) symptoms), notes that there are no published clinical trials of isolated apigenin (only chamomile-extract studies), and flags isolated apigenin’s instability and poor oral bioavailability as a quality concern.

Systematic Reviews

This section presents the most relevant systematic reviews and meta-analyses evaluating apigenin’s biological and therapeutic effects, with the caveat that current pooled evidence is dominated by preclinical (animal and in vitro) data rather than human trials.

• Apigenin in Cancer Prevention and Therapy: A Systematic Review and Meta-Analysis of Animal Models - Singh et al., 2022

  A systematic review and meta-analysis of 25 in vivo animal studies of apigenin across multiple cancer types, finding statistically significant pooled reductions in tumor volume (standardized mean difference (SMD, a unitless effect-size metric used in meta-analyses to combine studies measuring outcomes on different scales) -3.60), tumor weight (-2.21), tumor number (-1.08), and tumor load (-1.56), with no significant effect on body weight, while flagging publication-bias asymmetry and the absence of any completed human cancer trial.

• Potential Therapeutic Effects of Apigenin for Colorectal Adenocarcinoma: A Systematic Review and Meta-Analysis - Ahmadzadeh et al., 2024

  A meta-analysis of 39 preclinical studies (37 in vitro and 8 in vivo) showing that apigenin reduces colorectal cancer cell viability, induces growth inhibition, apoptosis, and cell-cycle arrest, and decreases tumor size in animal models, with the authors explicitly cautioning that further in vivo work is needed before any clinical translation.

• The Effects of Apigenin Administration on the Inhibition of Inflammatory Responses and Oxidative Stress in the Lung Injury Models: A Systematic Review and Meta-Analysis of Preclinical Evidence - Rahimi et al., 2022

  A meta-analysis of preclinical lung-injury studies finding that apigenin significantly reduces inflammatory and oxidative-stress markers (NF-κB; IL-1β, IL-6, TNF-α (interleukin-1β, interleukin-6, and tumor necrosis factor-alpha — pro-inflammatory cytokines); MDA (malondialdehyde, a marker of lipid peroxidation); MPO (myeloperoxidase, a neutrophil-derived oxidant enzyme); TGF-β (transforming growth factor-beta, a regulator of fibrosis)) while increasing antioxidant defenses (CAT (catalase), GSH (glutathione, the cell’s principal endogenous antioxidant), SOD (superoxide dismutase)), with the authors emphasizing that clinical trials and detailed human pharmacokinetic studies are needed before clinical use.

• Systemic Meta-Analysis: Apigenin’s Effects on Lung Inflammation and Oxidative Stress - Wang et al., 2024

  A systematic review and meta-analysis of five rat acute-lung-injury studies (226 animals) reporting that apigenin at 10 mg/kg and 20 mg/kg significantly reduces inflammatory mediators and oxidative stress markers compared with injury controls, while concluding that prospective controlled randomized human trials are required to confirm therapeutic value.

• Efficacy and Safety of Natural Apigenin Treatment for Alzheimer’s Disease: Focus on In Vivo Research Advancements - Zhang et al., 2025

  A systematic review and meta-analysis of 13 preclinical studies (736 animals) on apigenin in Alzheimer’s disease models, finding that apigenin reduced escape latency and increased target-quadrant time on memory tasks, lowered NF-κB p65 levels, increased SOD and GSH-px while decreasing MDA, and reduced caspase-3 levels and hippocampal apoptotic cells, with the authors concluding that further clinical studies are needed to confirm efficacy in humans.

Mechanism of Action

Apigenin (4’,5,7-trihydroxyflavone, C15H10O5) is a flavone — a subclass of flavonoid built around the flavone backbone (two phenyl rings connected by a heterocyclic pyrone ring) and decorated with three hydroxyl groups at positions 4’, 5, and 7. In food, apigenin occurs predominantly as glycosides such as apiin (apigenin-7-O-(2’‘-O-apiosyl)glucoside) and apigenin-7-glucoside, which are deglycosylated by gut microbiota and intestinal enzymes prior to absorption. The aglycone form has very low intrinsic aqueous solubility (~2.4 µg/mL) and modest oral bioavailability, with most absorbed apigenin appearing in plasma as the glucuronide (apigenin-4’-glucuronide) and sulfate conjugates.

Key pharmacological properties: parent apigenin appears at peak plasma concentrations 2–7 hours after intake (depending on the food matrix), with peak conjugate concentrations typically below 200 nmol/L from dietary doses. Plasma elimination half-life is approximately 90 minutes for the conjugates after typical food intake, though tissue retention in the liver and gut may be longer. Apigenin is metabolized through Phase I oxidation by CYP1A2 (Cytochrome P450 1A2, an enzyme involved in the metabolism of caffeine, melatonin, and several drugs) to a small extent and predominantly through Phase II conjugation by UGT1A1 (uridine 5’-diphospho-glucuronosyltransferase 1A1, the enzyme also responsible for bilirubin glucuronidation and known to vary by Gilbert syndrome polymorphisms), UGT1A3, UGT1A8, UGT1A9, UGT1A10 (additional uridine 5’-diphospho-glucuronosyltransferase isoforms that add glucuronic acid to substrates), and SULT1A1 (sulfotransferase 1A1, an enzyme that adds sulfate groups to drug substrates). Apigenin and its metabolites are excreted in urine and bile, with urinary recovery in humans ranging from 0.2% (apigenin aglycone) to 34% (chamomile-tea apigenin-7-glucoside). It is not selective for a single receptor; it acts as a polypharmacological compound across multiple targets.

Key mechanisms include:

• CD38 inhibition and NAD+ elevation: Apigenin is a competitive inhibitor of CD38 (Cluster of Differentiation 38, a glycoprotein that consumes cellular nicotinamide adenine dinucleotide). In mice, oral apigenin elevates tissue nicotinamide adenine dinucleotide levels and improves metabolic markers in obesity-prone strains; in human trials this mechanism has not been directly confirmed
• GABAergic and anxiolytic-like activity: Apigenin binds to the benzodiazepine site of the gamma-aminobutyric-acid type A receptor (the GABA-A receptor mediates fast inhibitory neurotransmission in the brain). Unlike benzodiazepines, apigenin functions as a partial agonist or weak modulator, producing anxiolytic-like and mildly sedative effects in rodents at relatively high doses without classic benzodiazepine motor or cognitive impairment
• Anti-inflammatory and antioxidant signaling: Apigenin inhibits NF-κB (Nuclear Factor kappa-light-chain-enhancer of activated B cells, a transcription factor central to inflammatory gene expression), MAPK (mitogen-activated protein kinase, a family of signaling enzymes that respond to stress and inflammatory stimuli), and pro-inflammatory cytokines (TNF-α, IL-1β, IL-6). It activates the Nrf2 pathway (Nuclear factor erythroid 2-related factor 2, a master regulator of cellular antioxidant defense), upregulating CAT (catalase), SOD (superoxide dismutase), and GSH (glutathione, the cell’s principal endogenous antioxidant)
• Anticancer pathways: Apigenin induces cell-cycle arrest at G2/M and apoptosis in numerous cancer cell lines, downregulates PI3K/Akt/mTOR (Phosphoinositide 3-Kinase/Protein Kinase B/mechanistic Target of Rapamycin, a growth-promoting signaling cascade), inhibits matrix metalloproteinases MMP-2 and MMP-9 (enzymes that facilitate cancer invasion and metastasis), and modulates estrogen-receptor-β signaling. Effects on senescent cell secretion (senescence-associated secretory phenotype) have been documented in cell models
• Mitohormesis and longevity signaling: In Caenorhabditis elegans, apigenin transiently inhibits mitochondrial respiration, generating a brief reactive oxygen species pulse that activates AMPK (AMP-activated protein kinase, a cellular energy sensor), DAF-16/FOXO (Forkhead box O, a transcription factor that promotes stress resistance), and SKN-1/Nrf-2, producing lifespan extension. In yeast and Drosophila, apigenin extends lifespan via the PTEN-AKT pathway (Phosphatase and tensin homolog/Protein Kinase B, a tumor-suppressor and growth-regulator axis)
• Hormonal modulation: Apigenin is a phytoestrogen with weak estrogen-receptor-β agonist and estrogen-receptor-α antagonist activity, an aromatase inhibitor in vitro, and a modulator of cortisol synthesis in human adrenocortical cell models. These actions underlie reports of menopausal-symptom modulation and possible blunting of estrogen-driven tumor promotion, but also raise theoretical concerns about hormonally sensitive populations

Competing mechanistic perspectives exist on whether apigenin’s preclinical findings translate to humans at achievable plasma concentrations. Skeptics note that the in vitro concentrations producing the most striking anticancer and senolytic effects (10–100 µM) are typically several orders of magnitude above plasma levels achieved by realistic dietary or supplemental dosing in humans. Proponents counter that tissue-specific accumulation, conjugate biological activity, and microbiome-derived metabolites may rescue meaningful in vivo effects.

Historical Context & Evolution

Apigenin has been recognized as a chemical constituent of plants since the 19th century, when it was isolated as a yellow flavone pigment from chamomile (Matricaria chamomilla) and parsley (Petroselinum crispum). Chamomile preparations had been used in European, Egyptian, and Greek herbal traditions for two millennia for digestive complaints, anxiety, and skin irritations, but the active flavone was only chemically characterized in the early 1900s. Throughout most of the 20th century, apigenin was treated primarily as a marker of chamomile extract quality and a contributor to the antimicrobial and anti-inflammatory effects of various herbal teas, with little research interest in the isolated molecule.

The shift toward apigenin as a candidate health-modifying compound began with chemoprevention research in the 1990s and 2000s, as flavones drew attention for their consistent anticancer activity in cell lines. A landmark 2010 review by Shukla and Gupta in Pharmaceutical Research helped consolidate the case for apigenin as a “promising molecule for cancer prevention,” catalyzing a rapid expansion of in vitro and animal studies through the 2010s.

Three subsequent developments brought apigenin into longevity-focused supplement culture: the 2013 publication by Escande et al. identifying apigenin as a CD38 inhibitor and showing in mice that this elevates tissue nicotinamide adenine dinucleotide; the popularization of a 50 mg pre-bedtime apigenin protocol by Andrew Huberman in 2021–2022 as part of his sleep cocktail; and the 2024 narrative review by Kramer and Johnson at Tally Health, which framed apigenin as a unique molecule positioned at the intersection of sleep and aging. Skeptics including ConsumerLab and several academic commentators have emphasized that, despite this enthusiasm, no published human randomized controlled trial of isolated apigenin had appeared by early 2026; nearly all human evidence rests on chamomile-extract trials of varying apigenin content. The original preclinical literature, the chamomile-extract trials, and the academic skepticism are all available for inspection.

Expected Benefits

Low 🟩

Sleep Onset and Sleep Quality Support ⚠️ Conflicted

The primary direct human evidence comes from chamomile-extract trials (chamomile contains apigenin as one of several active flavones), which have reported modest improvements in sleep latency, sleep quality, and daytime functioning, particularly in older adults with insomnia and in postpartum women. The 2008 Zick et al. trial of chamomile extract in chronic primary insomnia reported a non-significant trend toward improved sleep, while a 2017 trial in elderly patients reported significant improvement in sleep quality. A large-cohort dietary intake analysis cited in the 2024 Kramer and Johnson narrative review found a positive correlation between dietary apigenin intake and self-reported sleep quality. Direct trials of isolated apigenin at the popularized 50 mg dose are not yet published in peer-reviewed form. Mechanistically, apigenin acts at the GABA-A benzodiazepine site, providing biological plausibility, but the magnitude of effect at typical doses in humans is unclear and some users report no perceptible benefit.

Magnitude: Chamomile-extract trials report sleep quality improvements of approximately 0.5–1 point on Pittsburgh Sleep Quality Index scales; sleep onset latency reductions of 5–15 minutes in some trials; pooled effect sizes for isolated apigenin not established.

Anxiety and Mood Support

The strongest human evidence on apigenin-bearing preparations comes from chamomile-extract trials in generalized anxiety disorder. The 2009 and 2016 Amsterdam et al. trials of standardized chamomile extract (1.2% apigenin) at 1500 mg/day demonstrated significant reductions in Hamilton Anxiety Rating Scale scores compared with placebo, with effect sizes comparable to mild pharmacological anxiolytics. Subsequent trials have replicated anxiolytic effects with mixed magnitude. The 2024 Mohsenzadeh-Ledari trial of Matricaria chamomilla in menopausal women reported improvements in anxiety and depressive symptoms. Mechanistic support comes from apigenin’s GABA-A benzodiazepine-site binding and modest cortisol-suppressing activity in adrenocortical cell models.

Magnitude: Chamomile-extract trials report Hamilton Anxiety Rating Scale reductions of 4–8 points with 8–12 weeks of supplementation; isolated-apigenin equivalents not directly studied.

Anti-Inflammatory and Antioxidant Effects

Across preclinical models and a small set of human chamomile-extract trials, apigenin reduces systemic and tissue markers of inflammation and oxidative stress. The 2022 Rahimi et al. preclinical meta-analysis quantified large reductions in NF-κB expression, IL-1β, IL-6, and TNF-α in animal lung injury models, alongside large increases in catalase, glutathione, and superoxide dismutase. Small chamomile-extract trials in inflammatory conditions (oral mucositis, allergic rhinitis, type 2 diabetes complications) have reported reductions in C-reactive protein and oxidative stress markers, though with substantial variability.

Magnitude: Animal models show large standardized mean differences (>3) for inflammatory and antioxidant markers; human chamomile trials report C-reactive protein reductions of 15–30% in some studies; isolated apigenin in humans not quantified.

Speculative 🟨

Anticancer Activity

In vitro and animal data are strikingly consistent: apigenin induces apoptosis, cell-cycle arrest, and reduced tumor growth across breast, prostate, lung, colon, pancreatic, hepatic, skin, and head-and-neck cancer models. The 2022 Singh et al. meta-analysis of 25 in vivo animal studies reported significant pooled reductions in tumor volume, weight, number, and load. The 2024 Ahmadzadeh et al. systematic review confirmed similar effects specifically in colorectal adenocarcinoma models. Despite this preclinical depth, no completed human cancer prevention or treatment trial of isolated apigenin has been published; one Ohio State University trial in high-risk breast clinic patients was withdrawn before enrollment, and observational dietary apigenin-cancer associations are confounded by the broader dietary pattern.

Healthspan and Lifespan Extension

Multiple model-organism studies have reported lifespan extension with apigenin. In Caenorhabditis elegans, apigenin and apigenin glycosides extend lifespan via mitohormesis (transient mitochondrial inhibition triggering adaptive stress resistance) involving AMPK, DAF-16/FOXO, and SKN-1/NRF-2. In Saccharomyces cerevisiae and Drosophila melanogaster, apigenin extends both replicative and chronological lifespan via the PTEN-AKT-FOXO axis. In rodent CD38-knockout models, apigenin’s nicotinamide adenine dinucleotide-elevating effects improve metabolic and possibly cognitive aging markers. Direct human lifespan or healthspan trial evidence is absent.

Cognitive and Neuroprotective Support

Apigenin has been shown in rodent models to enhance neurogenesis, dendritic complexity, and learning and memory; in Alzheimer’s-model mice it reduces amyloid burden and neuroinflammation; and in Parkinson’s models it preserves dopaminergic neurons. The 2024 Kramer and Johnson review cited dietary apigenin intake as positively correlated with cognitive function in observational data. Direct human trials of apigenin for cognitive endpoints remain limited to chamomile-extract studies in older adults, with mixed results.

Cardiovascular and Endothelial Support

Apigenin and apigenin-rich extracts have been shown in cell and animal models to improve endothelial function, reduce vascular oxidative stress, and modestly lower blood pressure via inhibition of angiotensin-converting enzyme and increased nitric-oxide bioavailability. The 2016 NCT04114916 trial of an apigenin-luteolin-grapefruit-citrolive nutraceutical reported small reductions in cholesterol and improvements in endothelial function over 8 weeks, though apigenin’s specific contribution cannot be isolated from the multi-ingredient formulation.

Senolytic and Senomorphic Activity

In cell culture, apigenin reduces the senescence-associated secretory phenotype, suppressing inflammatory cytokine release from senescent cells. Some commentators describe apigenin as senomorphic (suppressing the secretome of senescent cells) rather than senolytic (selectively killing them). Direct human evidence is absent; commercial senolytic stacks combining apigenin with quercetin, fisetin, and theaflavins are marketed but unstudied in long-term human trials.

Glycemic Control

Apigenin reduces fasting glucose, improves insulin sensitivity, and protects pancreatic β-cells in rodent models of type 2 diabetes. Preliminary chamomile-extract trials in adults with type 2 diabetes have reported small reductions in HbA1c (Glycated Hemoglobin, a marker of average blood sugar over 2–3 months) and fasting glucose; isolated apigenin has not been studied in human metabolic trials.

Benefit-Modifying Factors

• Genetic polymorphisms: Variants in UGT1A1 and CYP1A2 may modify systemic exposure to apigenin and its conjugates, with low-activity UGT1A1 alleles theoretically increasing aglycone availability and CYP1A2 polymorphisms (e.g., CYP1A2*1F, an allele associated with altered enzyme inducibility) potentially affecting clearance. No validated pharmacogenomic dosing guidance is established
• Baseline biomarker levels: Adults with elevated baseline anxiety scores, sleep complaints, inflammatory markers, or oxidative stress markers tend to show the largest improvements in chamomile-extract trials. Adults with normal baseline anxiety and sleep show smaller and less reliable responses
• Sex-based differences: Apigenin’s phytoestrogenic activity may produce sex-specific effects. Some commentators (notably Andrew Huberman) have advised against apigenin use in women due to its mild estrogen-receptor-α-antagonist activity and possible interference with endogenous estrogen signaling, although the magnitude of this effect at 50 mg/day in humans is not clinically established. Anxiolytic effects of chamomile extract have been documented in both sexes
• Pre-existing health conditions: Adults with generalized anxiety disorder, chronic insomnia, or postpartum mood concerns appear to derive the most consistent symptomatic benefit from chamomile-derived apigenin. Adults with confirmed type 2 diabetes or metabolic syndrome may experience modest metabolic benefit, though direct isolated-apigenin evidence is lacking
• Age-related considerations: Older adults (60+) show the most consistent sleep-quality and anxiety improvement signals in chamomile trials. The CD38-NAD+ axis is most relevant to older adults given age-related nicotinamide adenine dinucleotide decline, although translation to clinical benefit in humans is unproven

Potential Risks & Side Effects

Low 🟥

Allergic Reactions to Source Plants

Chamomile, parsley, and other Asteraceae and Apiaceae family plants — the principal dietary sources of apigenin — produce IgE-mediated (Immunoglobulin E, the antibody class that drives immediate-type allergic reactions) hypersensitivity reactions in susceptible individuals, including contact dermatitis, urticaria, allergic rhinitis, and rare anaphylaxis. Cross-reactivity with ragweed, mugwort, and chrysanthemum is well documented. The reaction is generally to the source plant proteins and resins rather than to purified apigenin, but extracts may carry residual allergens.

Magnitude: Approximately 1–2% of chamomile users report skin or allergic symptoms; severe reactions are rare but documented in case reports.

Sedation and Drowsiness

Apigenin’s GABA-A benzodiazepine-site activity can produce mild sedation, drowsiness, and morning grogginess at higher doses (≥100 mg) or when combined with other central-nervous-system depressants. The effect is generally modest at the popularized 50 mg pre-bedtime dose but may impair alertness in occasional users. Concurrent alcohol use can amplify sedation.

Magnitude: Mild morning grogginess reported in approximately 5–10% of users at doses ≥100 mg; rarely reported at 50 mg in informal reports.

Speculative 🟨

Hormonal Modulation Concerns

Apigenin exhibits weak phytoestrogenic activity (estrogen-receptor-β agonist, estrogen-receptor-α antagonist) and aromatase-inhibitory activity in vitro. Some commentators have raised theoretical concerns about chronic high-dose use in women of reproductive age, in pregnancy and lactation, and in adults with hormonally sensitive cancers (estrogen-receptor-positive breast cancer, endometrial cancer). In vivo human data quantifying clinically meaningful hormonal effects at typical supplemental doses are absent; reassuring indirect evidence comes from the long history of chamomile tea consumption without documented endocrine harm.

Anticoagulant Interaction Risk

Chamomile and some other apigenin sources contain coumarin-like compounds, and in vitro studies show apigenin can inhibit platelet aggregation. Two published Stony Brook University crossover trials of chamomile in healthy volunteers (NCT05272475 and NCT05006378) examined the question and reported no acute clinically meaningful coagulation changes, but the underlying mechanism is biologically plausible at high concentrated doses. Combined use with warfarin, direct oral anticoagulants, or high-dose nonsteroidal anti-inflammatory drugs has been associated with isolated bleeding case reports.

Drug Metabolism Interference

Apigenin is a documented in vitro inhibitor of CYP1A2, CYP2C9, CYP3A4 (Cytochromes P450 isoforms responsible for metabolizing a large share of pharmaceutical drugs), and several uridine 5’-diphospho-glucuronosyltransferase isoforms. The 2023 Raish et al. study showed that apigenin altered the pharmacokinetics of dasatinib (a tyrosine kinase inhibitor used in chronic myeloid leukemia) in animal models. Clinically meaningful drug-drug interactions in humans at typical 50 mg apigenin doses are theoretical but plausible, particularly for narrow-therapeutic-index drugs.

Pregnancy and Lactation Safety

Whole-food apigenin sources (parsley, celery, chamomile tea) are widely consumed during pregnancy without documented harm at culinary doses. Concentrated apigenin supplements have not been formally evaluated in pregnancy or lactation; product labels and Examine guidance recommend avoidance. High-dose parsley extract has historically been associated with uterine-stimulating effects in folk medicine (a concern unrelated specifically to apigenin but relevant to source-plant supplements).

Supplement Quality Variability

Isolated apigenin is chemically unstable and poorly soluble in water (~2.4 µg/mL), and ConsumerLab notes that essentially all human studies have been conducted with plant-extract preparations rather than isolated compound. Marketed apigenin supplements vary widely in actual apigenin content, particle size, and excipient delivery system (liposomal, nanoemulsion, or simple powder), with limited independent verification of label claims. This is principally a quality-control concern rather than a direct toxicity issue.

Risk-Modifying Factors

• Genetic polymorphisms: No specific polymorphisms have been characterized as meaningfully modifying apigenin safety. Adults with documented Asteraceae allergy (genetic predisposition to atopic disease) face elevated risk from chamomile-derived sources. Variability in UGT1A1 and CYP1A2 may theoretically alter exposure to active metabolites
• Baseline biomarker levels: Adults on warfarin with unstable INR (International Normalized Ratio, a measure of how long blood takes to clot, used to monitor warfarin therapy), adults with elevated bleeding risk, or adults with hormonally sensitive tumor biomarkers (e.g., estrogen-receptor-positive breast cancer survivors) warrant additional caution
• Sex-based differences: Women of reproductive age, pregnant women, and breastfeeding women face heightened theoretical risk from apigenin’s phytoestrogenic activity at supplemental doses; whole-food chamomile tea intake remains broadly considered safe at typical amounts. Women with histories of estrogen-sensitive cancers may want to avoid concentrated supplements pending more data
• Pre-existing health conditions: Adults with documented chamomile, parsley, or ragweed allergy should avoid concentrated extracts of those sources. Adults with active inflammatory bowel disease may experience exaggerated gastrointestinal effects from concentrated extracts. Adults with hormonally driven endocrine disorders, those scheduled for surgery within two weeks (theoretical bleeding risk), and those on multiple antiplatelet or anticoagulant agents warrant attention
• Age-related considerations: Older adults more often take anticoagulants, antiplatelet agents, central nervous system depressants, and benzodiazepines, raising the theoretical risk of additive sedation and bleeding effects. Older adults may also have reduced hepatic conjugation capacity, modestly increasing exposure

Key Interactions & Contraindications

• Anticoagulant medications: Warfarin (an anticoagulant medication that depends on stable vitamin K intake for predictable dosing) and DOACs (Direct Oral Anticoagulants, such as apixaban, rivaroxaban, and dabigatran, which inhibit specific clotting factors) may have theoretically additive effects with concentrated apigenin extracts that include coumarin-like compounds. Severity: monitor. Mitigating action: maintain stable supplement dosing, monitor INR (in warfarin users) when initiating or stopping concentrated chamomile or apigenin products
• Antiplatelet medications: Aspirin, clopidogrel (an oral antiplatelet medication that prevents platelet aggregation), and similar agents may have small additive antiplatelet effects with concentrated apigenin extracts. Severity: monitor. Mitigating action: clinically meaningful additive effect from typical 50 mg apigenin doses is unlikely; high-dose extracts in combination with multiple antiplatelet agents warrant caution and discontinuation 7–14 days before elective surgery
• Central nervous system depressants: Benzodiazepines (alprazolam, diazepam, lorazepam — drugs that potentiate GABA-A signaling), Z-drugs (zolpidem, eszopiclone — non-benzodiazepine hypnotic medications), opioids, alcohol, and sedating antihistamines may produce additive sedation with apigenin’s GABAergic activity. Severity: caution. Mitigating action: avoid co-administration; if combined, start at the lower apigenin dose (25 mg) and avoid driving or hazardous activities
• CYP-substrate medications: Apigenin inhibits CYP1A2, CYP2C9, and CYP3A4 in vitro. Theoretically interacting drugs include warfarin (CYP2C9), theophylline (a CYP1A2 substrate used for asthma), tizanidine (a CYP1A2 substrate muscle relaxant), tacrolimus (a CYP3A4 substrate immunosuppressant), and many tyrosine kinase inhibitors (e.g., dasatinib, imatinib). Severity: monitor. Mitigating action: separate intake by 2–4 hours and monitor for unexpected drug effect intensification
• Antidiabetic medications: Insulin, sulfonylureas (a class of oral diabetes drugs that stimulate insulin release, such as glipizide and glyburide), and SGLT2 inhibitors (a class of diabetes drugs that block glucose reabsorption in the kidney, such as empagliflozin, dapagliflozin, and canagliflozin) may have small additive glucose-lowering effects with high-dose apigenin or concentrated chamomile. Severity: monitor. Mitigating action: monitor glucose during initiation in adults already on antidiabetic therapy
• Antihypertensive medications: Possible small additive blood-pressure effects with ACE inhibitors (Angiotensin-Converting Enzyme inhibitors, a class of blood-pressure-lowering drugs), ARBs (Angiotensin Receptor Blockers), and calcium-channel blockers. Severity: monitor. Mitigating action: routine blood-pressure monitoring during initiation in adults already on antihypertensive therapy
• Hormonal therapies: Possible interference with estrogen-replacement therapy, oral contraceptives, tamoxifen (a selective estrogen receptor modulator used in estrogen-receptor-positive breast cancer), and aromatase inhibitors (anastrozole, letrozole — drugs that block estrogen synthesis used in breast cancer). Severity: caution. Mitigating action: discuss with prescribing oncologist; avoid in tamoxifen and aromatase-inhibitor users without specialist clearance
• Over-the-counter medications: No significant interactions are documented with common OTC analgesics, proton-pump inhibitors, or antacids. NSAIDs (Non-Steroidal Anti-Inflammatory Drugs, such as ibuprofen and naproxen) at high doses combined with concentrated apigenin extracts may marginally compound antiplatelet effects. Severity: monitor at high combined doses
• Supplement interactions and additive effects: Magnesium, theanine, glycine, GABA, melatonin, and valerian may have additive sedative effects (often desired for sleep stacks but can produce excessive morning grogginess). Quercetin, fisetin, theaflavins, and resveratrol have additive senomorphic/anti-inflammatory effects (often used together intentionally in senolytic stacks). Curcumin, omega-3 fatty acids, and high-dose vitamin E may add to weak antiplatelet effects. Severity: generally monitor; introduce one product at a time to gauge individual response
• Other intervention interactions: Co-ingestion of apigenin with high-fat meals modestly increases bioavailability of the aglycone form. Severity: minor; relevant for protocol consistency only
• Populations who should avoid or limit apigenin supplements: Adults with documented IgE-mediated allergy to chamomile, parsley, ragweed, mugwort, or related Asteraceae/Apiaceae plants (particularly those with prior anaphylactic episode or positive skin-prick or specific-IgE result). Pregnant women (any trimester) and breastfeeding women (exclusive breastfeeding through ~6 months postpartum) should avoid concentrated apigenin extract supplements. Adults on warfarin with unstable INR, adults scheduled for elective surgery within 14 days, adults with active estrogen-receptor-positive breast cancer or endometrial cancer, and adults on tamoxifen or aromatase inhibitors should avoid concentrated apigenin supplements pending more data. Women of reproductive age desiring conception may prefer to limit chronic concentrated supplementation

Risk Mitigation Strategies

• Prefer dietary sources before concentrated supplements: Whole-food apigenin sources (chamomile tea, parsley, celery, oranges, oregano, thyme, artichoke) deliver apigenin alongside fiber and other plant compounds, with negligible documented adverse events at typical dietary intakes — addressing the allergic-reaction, hormonal-modulation, and quality-variability concerns associated with concentrated extracts
• Choose third-party-tested supplements when supplementing: When using concentrated apigenin, select products with third-party verification (NSF, USP, ConsumerLab, or Informed Choice) of apigenin content and purity, addressing the documented variability in marketed products and concerns about isolated apigenin’s chemical instability
• Start at low doses and titrate gradually: Begin concentrated apigenin at 25 mg before bed for the first week and increase to 50 mg as tolerated, mitigating the sedation and morning-grogginess risk reported at higher initial doses
• Take pre-bedtime, not earlier: Take supplemental apigenin 30–60 minutes before intended sleep onset, mitigating daytime sedation risk and aligning with the GABAergic mechanism
• Monitor for additive sedation when combining with other sleep agents: Adults using benzodiazepines, Z-drugs, alcohol, opioids, or sedating antihistamines should avoid concurrent apigenin or use the lowest effective dose, addressing additive central-nervous-system depression risk
• Avoid concentrated extracts in pregnancy and lactation: Whole-food chamomile tea in moderate amounts has a long history of use during pregnancy without documented harm, but concentrated supplemental extracts lack pregnancy and lactation safety data and should be avoided unless specifically directed by a clinician
• Hold before elective surgery: Discontinue concentrated apigenin supplements 7–14 days before elective surgery to mitigate theoretical bleeding-risk increases from additive antiplatelet effects, particularly in patients on aspirin or other antiplatelet therapy
• Discuss with oncologist if hormonally sensitive cancer history: Patients with histories of estrogen-receptor-positive breast cancer, endometrial cancer, or current tamoxifen or aromatase-inhibitor therapy should obtain specialist clearance before concentrated apigenin supplementation to avoid theoretical interference with hormonal therapy

Therapeutic Protocol

The most commonly used apigenin intake patterns derive from doses popularized in widely shared sleep-stack protocols, traditional chamomile tea preparations, and the limited human evidence available. The dominant protocol — popularized by Andrew Huberman and adopted in commercial products such as Momentous Apigenin and Life Extension Senolytic Activator — is 50 mg taken 30–60 minutes before bedtime. Conventional and integrative approaches differ on whether to prefer concentrated apigenin, whole-food chamomile tea, or multi-flavonoid senolytic stacks; clinical trials have tested only the chamomile-extract preparations directly. Peter Attia describes apigenin as “reasonable to try, not essential” within a broader sleep regimen.

• Standard daily intake (sleep-stack protocol): 50 mg apigenin taken 30–60 minutes before bedtime, typically with magnesium threonate (140 mg elemental magnesium) and L-theanine (200–400 mg). This dose is informed by Huberman’s published recommendations rather than head-to-head dose-finding trials
• Higher-dose protocol (senomorphic and anti-inflammatory targets): 100–200 mg apigenin taken once daily with food. This dose is used in some senolytic-flavonoid stacks but lacks direct human trial validation. Sedation and morning grogginess become more common at this range
• Whole-food chamomile-extract protocol (anxiety-targeted): 1100–1500 mg standardized chamomile extract (typically standardized to 1.2% apigenin) twice daily, the regimen used in the Amsterdam et al. generalized anxiety disorder trials. This delivers approximately 26–36 mg apigenin daily in a complex extract matrix
• Best time of day: Pre-bedtime is favored when the target is sleep onset and sleep quality. For anti-inflammatory or hormonal targets, morning or split dosing with food may be preferred to align with daytime cortisol and inflammatory rhythms; evidence guiding this choice is sparse
• Half-life: Plasma half-life of apigenin conjugates is approximately 90 minutes after dietary intake; tissue retention in the liver, gut, and adipose tissue may extend the functional duration. Bioavailability of the aglycone is poor (typically <1% urinary recovery from concentrated parsley intake), with significantly higher recovery from chamomile glycoside forms (up to 34%) due to upper-gastrointestinal absorption
• Single dose vs. split doses: A single pre-bedtime dose is most studied for sleep targets. For systemic anti-inflammatory or longevity targets, split dosing twice daily may produce smoother systemic exposure, though no head-to-head trials have shown a clinical advantage
• Genetic polymorphisms: No pharmacogenomic dosing adjustments are established. Variability in UGT1A1 and CYP1A2 may modulate exposure but does not currently warrant individualized dosing
• Sex-based differences: Standard doses apply to both sexes. Andrew Huberman has explicitly recommended that women avoid concentrated apigenin due to possible estrogenic interference; this remains a precautionary stance not validated in dose-finding human trials. Women of reproductive age desiring conception or with hormonally sensitive cancer history may prefer to limit concentrated supplementation
• Age-related considerations: Older adults (60+) tend to show the most consistent sleep-quality and anxiety improvement signals in chamomile trials. Older adults with reduced hepatic conjugation capacity may experience modestly higher exposure and may benefit from starting at 25 mg rather than 50 mg
• Baseline biomarker levels: Adults with elevated anxiety scores, sleep complaints, or inflammatory markers (e.g., hs-CRP (high-sensitivity C-Reactive Protein, a sensitive marker of low-grade systemic inflammation) >1.0 mg/L) may benefit from the higher end of the dose range (75–100 mg). Adults without symptoms can use lower doses (25–50 mg) for maintenance
• Pre-existing health conditions: Adults with generalized anxiety disorder may benefit from the chamomile-extract protocol (1100–1500 mg standardized extract, twice daily) where direct human evidence exists. Adults with insomnia complaints may use 50 mg pre-bedtime as part of a multi-component stack with attention to sleep hygiene fundamentals

Discontinuation & Cycling

• Duration of use: Apigenin can be used short-term (during periods of acute sleep or anxiety challenge) or as a long-term daily supplement, with anecdotal reports of continuous use for years without dependence. Direct human safety data beyond 8–12 weeks of chamomile-extract trials are limited, and chronic high-dose isolated-apigenin safety has not been formally established
• Withdrawal effects: No physical withdrawal effects are reported on discontinuation. Sleep and anxiety symptoms gradually return to baseline over several days to weeks. Apigenin does not act on benzodiazepine sites with the affinity required for classical dependence
• Tapering protocol: No tapering is required. Apigenin supplementation can be discontinued abruptly without adverse effects. Adults using apigenin as part of a multi-component sleep stack who notice sleep disruption on discontinuation should examine whether the disruption is psychological (placebo dependence) or related to other concurrent agents
• Cycling: Cycling is not necessary for safety reasons. Some practitioners recommend periodic 1- to 2-week breaks every 2–3 months to reset perceived effect and avoid placebo dependence; this practice is not supported by trial data but carries minimal downside. For senolytic-flavonoid protocols, intermittent (e.g., 2 days per month) high-dose pulses are sometimes recommended in popular stacks but lack direct human evidence

Sourcing and Quality

• Whole-food sources: Highest apigenin densities (per 100 g fresh weight) are found in dried parsley (≈4500 mg per 100 g dried), chamomile flowers (≈3000–5000 mg per 100 g dried), fresh parsley (≈215 mg per 100 g), celery seed (≈790 mg per 100 g), celery hearts (≈19 mg per 100 g), dried oregano (≈240 mg per 100 g), and to lesser extent in artichokes, oranges, and grapefruit. Chamomile tea (1 tea bag steeped 5 minutes) typically delivers ≈2–10 mg apigenin equivalents, varying widely by product
• Standardized chamomile extracts: Chamomile extracts standardized to 1.2% apigenin (used in the Amsterdam anxiety trials) and 1.5–2% apigenin (used in some sleep formulations) provide reproducible delivery and are the most clinically tested form. Dose ranges of 1100–1500 mg twice daily approximate the regimen with the strongest human evidence for anxiolysis
• Concentrated apigenin extract supplements: 50 mg apigenin capsules (commonly marketed for sleep) are the most popular consumer form. Independent testing reveals substantial variability in actual apigenin content and purity between brands, and isolated apigenin’s poor solubility (~2.4 µg/mL) and chemical instability complicate quality control. Liposomal, nanoemulsion, and self-nanoemulsifying drug delivery system formulations claim improved bioavailability but lack consistent human pharmacokinetic verification
• Reputable suppliers and brands: For chamomile tea, brands such as Traditional Medicinals, Pukka, and Yogi have established quality reputations. For chamomile extract supplements, Pure Encapsulations, Thorne, and Gaia Herbs are commonly cited. For concentrated apigenin, Momentous (Andrew Huberman partner brand), Life Extension (Senolytic Activator with apigenin, quercetin, theaflavins, and bio-fisetin), Double Wood Supplements, Nootropics Depot, and Vitality Pro have third-party-testing programs of varying rigor. Product testing results vary by batch
• Stability and storage: Apigenin is moderately heat- and light-sensitive in extracted form. Tea preparations should be steeped in covered containers and consumed shortly after preparation. Capsules should be stored cool, dry, and away from direct sunlight, with tight resealing of the bottle. Liposomal liquid formulations typically require refrigeration after opening
• Pesticide residue considerations: Conventional parsley, celery, and chamomile flowers appear on environmental monitoring lists for elevated pesticide-residue exposure. Certified organic sources or thorough rinsing reduce this exposure; for chamomile tea specifically, organic certification is widely available and recommended

Practical Considerations

• Time to effect: Acute sedative and anxiolytic effects (when present) can be detected within 30–90 minutes of a 50 mg dose. Chamomile-extract anxiolytic effects typically require 4–8 weeks of consistent twice-daily use to reach maximum benefit. Senomorphic, anti-inflammatory, and longevity-targeted effects (where they apply at all in humans) likely require months of consistent intake without a clear timeline established by trials
• Common pitfalls: Frequent mistakes include treating apigenin as a stand-alone replacement for sleep hygiene fundamentals (light exposure, temperature, schedule consistency) rather than an adjunct; using poor-quality unstandardized chamomile teas or untested supplement brands and expecting clinical-trial doses; combining apigenin with alcohol or benzodiazepines and producing excessive grogginess; using high doses (≥200 mg) chronically without monitoring; women of reproductive age using concentrated extracts without considering theoretical hormonal effects; expecting the in vitro anticancer or senolytic effects to replicate in humans at typical supplemental doses; and discounting the absence of any completed human RCT (Randomized Controlled Trial, a study in which participants are randomly assigned to a treatment or a control group) of isolated apigenin in interpreting marketing claims
• Regulatory status: Apigenin occurs naturally in many regulated foods and requires no specific FDA (Food and Drug Administration, the U.S. agency that regulates foods, drugs, and dietary supplements) approval. Apigenin and chamomile supplements are regulated as dietary supplements under DSHEA (Dietary Supplement Health and Education Act, the U.S. law governing dietary supplements), with less stringent pre-market quality scrutiny than for prescription drugs. Apigenin is not scheduled under controlled-substance laws
• Cost and accessibility: Whole-food apigenin sources (parsley, celery, chamomile tea) are widely available and inexpensive. Concentrated apigenin supplements (50 mg, 60–120 capsules) typically cost $0.20–$0.80 per daily serving depending on brand, formulation, and certification. Liposomal or nanoemulsion formulations cost more

Interaction with Foundational Habits

• Sleep: Apigenin’s pre-bedtime dosing is its most studied use case (direction: potentiating, modest). Mechanism: GABA-A benzodiazepine-site partial-agonist activity reduces ruminating thoughts and modestly accelerates sleep onset; cortisol-suppressing activity may further support sleep quality. Practical consideration: take 30–60 minutes before intended sleep onset; avoid pairing with alcohol or benzodiazepines; effects on sleep architecture (REM/NREM (Rapid Eye Movement / Non-Rapid Eye Movement, the two main stages of sleep) distribution) appear neutral to mildly favorable in chamomile-extract polysomnography studies
• Nutrition: Apigenin integrates well with whole-food, plant-rich diets (direction: potentiating, when paired with diverse polyphenol intake). Co-ingestion with high-fat meals modestly increases aglycone bioavailability. Practical consideration: chamomile tea, parsley garnish, celery, oranges, and oregano provide meaningful dietary apigenin without the cost or quality variability of supplements; the food matrix may also deliver complementary flavonoids (luteolin, chrysin) with overlapping activity
• Exercise: Apigenin may modestly reduce post-exercise oxidative stress and inflammatory markers (direction: potentiating, weak). Mechanism: Nrf2 activation and NF-κB inhibition, the same antioxidant and anti-inflammatory pathways implicated in apigenin’s preclinical anti-inflammatory profile. Practical consideration: at supraphysiological isolated doses (>200 mg/day), chronic high-dose flavonoid antioxidants have been hypothesized to blunt some training adaptations, though direct human apigenin data are absent; whole-food intake and standard supplemental doses (50 mg) are not expected to interfere with training
• Stress management: Apigenin shows modest anxiolytic effects in chamomile-extract trials and reduces cortisol synthesis in human adrenocortical cell models (direction: potentiating, modest). Practical consideration: apigenin may complement non-pharmacological stress practices (meditation, breathwork, cognitive behavioral therapy for insomnia) but should not replace foundational stress-management habits; combined use with prescription anxiolytics warrants attention to additive sedation

Monitoring Protocol & Defining Success

Baseline labs should be obtained before regularizing high-dose concentrated apigenin supplementation when the goal is anxiety, sleep, or systemic inflammatory marker improvement. Routine labs are not required for typical low-dose pre-bedtime use. Ongoing monitoring is appropriate at 4–8 weeks after initiation, then every 6–12 months thereafter, with closer attention for adults on antihypertensive, antidiabetic, anticoagulant, sedative, or hormonal therapy.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Pittsburgh Sleep Quality Index	<5 (good sleep)	Tracks sleep-quality response to apigenin	Self-administered questionnaire; PSQI = Pittsburgh Sleep Quality Index; reassess at 4 and 8 weeks
Hamilton Anxiety Rating Scale	<14 (mild or none)	Tracks anxiolytic response to apigenin	HAM-A = Hamilton Anxiety Rating Scale; clinician- or self-administered; baseline >18 in trial cohorts; reassess at 4–8 weeks
hs-CRP	<1.0 mg/L	Tracks low-grade systemic inflammation response	hs-CRP = high-sensitivity C-Reactive Protein; conventional reference range: <3.0 mg/L
Fasting Glucose	72–85 mg/dL	Tracks possible glycemic effect	Conventional reference range: 70–100 mg/dL; 12-hour fast required
HbA1c	4.8–5.2%	Long-term glycemic control marker	Conventional cutoff: <5.7% considered “normal”; reflects 2–3 month average glucose; HbA1c = Glycated Hemoglobin
Blood Pressure	SBP <120, DBP <80 mmHg	Tracks possible blood-pressure response	SBP = Systolic Blood Pressure; DBP = Diastolic Blood Pressure; morning measurement preferred
Liver Function Panel (ALT, AST)	ALT <25 (men) / <19 (women), AST <30 U/L	Routine safety monitoring at high chronic doses	ALT = Alanine Aminotransferase; AST = Aspartate Aminotransferase; conventional upper limits ~40 U/L
INR (warfarin users only)	Per clinician target	Safety monitoring for theoretical anticoagulant interaction	INR = International Normalized Ratio; check after any large change in supplemental apigenin intake

Qualitative markers to track include:

• Sleep onset latency, awakenings, and morning refreshment
• Anxiety levels, ruminating thoughts at night, and social-functioning ease
• Daytime alertness and absence of morning grogginess
• Mood, irritability, and stress reactivity
• Bowel regularity and tolerance of higher daily intakes
• Skin clarity and any signs of allergic reaction
• Menstrual cycle regularity in women using concentrated apigenin chronically

A brief daily journal during the first 4–8 weeks can help identify response patterns, sedation tolerance, and integration with other dietary or supplemental changes.

Emerging Research

Several active clinical trials and research directions may sharpen the evidence base for apigenin’s health and longevity applications:

• Apigenin for organ-function recovery in elderly sepsis patients: A completed Phase 1/2 trial (NCT05999682) at Zhujiang Hospital evaluated apigenin tablets 50 mg via gastric tube against sterile water in 20 elderly patients with sepsis to assess SOFA-score (Sequential Organ Failure Assessment, a tool to quantify organ dysfunction in critically ill patients) changes and clinically meaningful outcomes — the first published RCT of isolated apigenin in a clinical population, with results pending peer-review publication
• Apigenin-containing supplement combination for sleep and stress: A completed trial (NCT06889584) at the University of South Carolina enrolled 115 healthy adults to assess a multi-component supplement combination including ashwagandha, Rhodiola rosea, magnesium threonate, L-theanine, and apigenin on sleep quality and stress, with results awaited
• Apigenin-containing nutraceutical for chronic post-COVID inflammation: A trial (NCT07397910) at Universidad Católica San Antonio de Murcia is enrolling 40 adults with long-COVID hepato-pulmonary and neurovascular inflammation to evaluate an apigenin-containing experimental product, providing one of the few apigenin-targeted trials in a chronic inflammatory population
• Apigenin and crocin for Parkinson’s disease management: A trial (NCT05696665) at Jinnah Postgraduate Medical Centre in Pakistan is testing the saffron-and-chamomile active compounds crocin and apigenin combined with conventional therapy in 120 patients with Parkinson’s disease, evaluating Movement Disorder Society Unified Parkinson’s Disease Rating Scale, alpha-synuclein biomarkers, and oxidative stress markers
• Apigenin-containing nutraceutical for cardiovascular risk: A completed trial (NCT04114916) at Universidad Católica San Antonio de Murcia evaluated an apigenin-luteolin-grapefruit-citrolive nutraceutical against placebo over 8 weeks in 100 adults with elevated cholesterol, reporting modest improvements in cholesterol and endothelial function (apigenin’s specific contribution cannot be isolated from the multi-ingredient formulation)
• Pharmacokinetic and bioavailability research: The 2024 Sato et al. self-nanoemulsifying drug delivery system study and ongoing nanoformulation work aim to address apigenin’s poor bioavailability, which may enable future trials at meaningful systemic concentrations. The 2022 Borges et al. absorption-distribution-metabolism-excretion study (NCT03526081) characterized the metabolite profile in 17 healthy male adults and remains the most rigorous human pharmacokinetic data available
• Senomorphic and longevity research areas: Future research directions include direct human trials of apigenin’s CD38 inhibition and nicotinamide adenine dinucleotide-elevating effects, comparative trials against established senolytic regimens (dasatinib + quercetin, fisetin), and longer-duration trials in older adults targeting healthspan biomarkers. The 2024 Kramer & Johnson review explicitly calls for such trials. Findings from these could either strengthen or weaken current claims
• Methodological constraints and conflicts of interest in the field: A meaningful share of apigenin research is funded by chamomile-product manufacturers, supplement companies marketing apigenin (Tally Health, the publisher of the 2024 review, sells apigenin-containing products), and longevity-supplement-aligned non-profits (a structural conflict of interest applicable to a portion of the cited evidence base), which warrants weight when interpreting positive results, especially for endpoints with small effect sizes and absent independent confirmation

Conclusion

Apigenin is a flavone with extensive preclinical literature documenting anti-inflammatory, antioxidant, anticancer, anxiolytic, and lifespan-extending activity across cells, worms, flies, and rodents. The strongest direct human evidence comes not from isolated apigenin but from chamomile-extract trials, which show modest benefits for anxiety and sleep quality in adults with elevated baseline complaints. Pre-bedtime dosing of 50 mg has become a popular sleep-stack component thanks to widely shared expert protocols, despite the absence of any published trial directly testing isolated apigenin at this dose. Certainty of evidence is low across most outcomes and speculative for anticancer, longevity, senomorphic, and metabolic claims, reflecting the near-complete absence of human trials at supplemental concentrations. A meaningful share of human research and educational content on apigenin is produced by parties with direct financial interest in chamomile or apigenin product sales, a structural conflict worth weighing when interpreting positive findings.

The risk profile is favorable at typical doses. Whole-food and tea-based intake is well-tolerated. Concentrated supplements warrant attention to allergy in those sensitive to chamomile, parsley, or ragweed, additive sedation when combined with sleep medications, sedatives, or alcohol, theoretical hormonal effects in women of reproductive age and those with hormone-sensitive cancer histories, and theoretical bleeding risk when combined with blood thinners.

For health- and longevity-oriented adults, the evidence positions apigenin as a low-risk, mildly supportive addition to a sleep or anxiety protocol where foundational habits are in place, while broader anticancer and longevity claims remain preclinical-only.

Top - Benefits - Risks - Protocol